Features

Features

Accelerating diagnosis and drug development with better managed datasets

Every aspect of science and research is based on data, and across the globe, labs are producing more data than…

Features

A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm

Features

Podcast: US tariff news and Q2 earnings influence pharma trends

Features

Europe’s cannabis pharmaceuticals market matures amid cautious investment

Features

Targeting energy expenditure: the next wave of obesity drugs

Features

Synthetic rescue: Insmed explores a new frontier in genetic therapeutics

Features

Can rare disease research in the US thrive under the new administration?

Features

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Features

Why can’t the US figure out weight loss drug prices?

Features

How will RFK Jr’s American dream for vaccines play out?

Features

EHDS regulation will depend on strong patient confidence

Features

From discovery to delivery: making therapies reach patients faster

Features

Magazine: Are regulators keeping pace with AI adoption in clinical trials?

Features

Can pharma tariffs “Make America Manufacture Again”?

Frankie Fattorini

Features

Power of collaboration more pertinent than ever says pharma experts

Features

Newborn screening strategy needs modernising as HHS disbands advisory committee

Features

Pharma’s AI prospects get nudged into the future with EU’s AI act

Features

Are regulators keeping pace with AI adoption in clinical trials?

Awards

Introducing the Pharmaceutical Technology Excellence Awards 2025

Features

Entering the era of prenatal gene therapies

Features

Magazine: The GLP-1 shortage is over. What’s next for compounders?

Features

Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market

Features

FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline

Features

Podcast: What’s next for pharma tariffs?

Manasi Vaidya , Jenna Philpott and Abigail Beaney

Features

The GLP-1 drug shortage is over. What’s next for the compounders?

Features

Can AI replace medical writers? Experts say not immediately

Frankie Fattorini

Features

IRA holds the scope to shape pharma’s research strategy, say experts

Features

Magazine: Are European biopharma manufacturers ‘nearshoring’?

Features

Big pharma faces headwinds in China as vaccine sales decline

Features

Rising Sirturo resistance highlights urgent need for new TB therapies

Features

European agencies catch up with speedier regulatory pathways for CGTs in the US

Features

Amid deglobalising trade, experts seek AI safeguards for clinical trial supply

Frankie Fattorini

Features

Are European biopharma manufacturers ‘nearshoring’?

Frankie Fattorini

Features

Inborn errors of metabolism elicit unique challenges for therapy development

Features

Magazine: Radiopharmaceutical deals drive sector growth despite supply crisis

Features

OCT West Coast 2025: Recruitment and regulation remain pain points

Features

GLP-1RAs and opioid use disorder: a new frontier in addiction treatment

Features

EU reshapes HTAs: is the industry ready for it?

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close